JP2020507587A5 - - Google Patents

Download PDF

Info

Publication number
JP2020507587A5
JP2020507587A5 JP2019543800A JP2019543800A JP2020507587A5 JP 2020507587 A5 JP2020507587 A5 JP 2020507587A5 JP 2019543800 A JP2019543800 A JP 2019543800A JP 2019543800 A JP2019543800 A JP 2019543800A JP 2020507587 A5 JP2020507587 A5 JP 2020507587A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antibody
subject
aureus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019543800A
Other languages
English (en)
Japanese (ja)
Other versions
JP7145162B2 (ja
JP2020507587A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/000209 external-priority patent/WO2018150265A1/en
Publication of JP2020507587A publication Critical patent/JP2020507587A/ja
Publication of JP2020507587A5 publication Critical patent/JP2020507587A5/ja
Priority to JP2022147604A priority Critical patent/JP2022188083A/ja
Application granted granted Critical
Publication of JP7145162B2 publication Critical patent/JP7145162B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019543800A 2017-02-16 2018-02-16 化膿性汗腺炎の処置 Active JP7145162B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022147604A JP2022188083A (ja) 2017-02-16 2022-09-16 化膿性汗腺炎の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762459841P 2017-02-16 2017-02-16
US62/459,841 2017-02-16
PCT/IB2018/000209 WO2018150265A1 (en) 2017-02-16 2018-02-16 Treatment of hidradenitis suppurativa

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022147604A Division JP2022188083A (ja) 2017-02-16 2022-09-16 化膿性汗腺炎の処置

Publications (3)

Publication Number Publication Date
JP2020507587A JP2020507587A (ja) 2020-03-12
JP2020507587A5 true JP2020507587A5 (enExample) 2021-03-25
JP7145162B2 JP7145162B2 (ja) 2022-09-30

Family

ID=63170129

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019543800A Active JP7145162B2 (ja) 2017-02-16 2018-02-16 化膿性汗腺炎の処置
JP2022147604A Pending JP2022188083A (ja) 2017-02-16 2022-09-16 化膿性汗腺炎の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022147604A Pending JP2022188083A (ja) 2017-02-16 2022-09-16 化膿性汗腺炎の処置

Country Status (12)

Country Link
US (5) US11225517B2 (enExample)
EP (1) EP3582813A4 (enExample)
JP (2) JP7145162B2 (enExample)
KR (1) KR20190117579A (enExample)
CN (1) CN110382001A (enExample)
AU (1) AU2018220862A1 (enExample)
CA (1) CA3053231A1 (enExample)
IL (1) IL268569A (enExample)
MX (1) MX2019009798A (enExample)
PH (1) PH12019501900A1 (enExample)
SG (1) SG11201907159SA (enExample)
WO (1) WO2018150265A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159976A2 (en) 2010-06-18 2011-12-22 Xbiotech, Inc. Arthritis treatment
CN103153340A (zh) 2010-08-23 2013-06-12 埃克斯生物科技公司 对肿瘤疾病的治疗
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
TWI737000B (zh) * 2018-10-22 2021-08-21 美商美國禮來大藥廠 用於治療化膿性汗腺炎之泛-elr+cxc趨化介素抗體
TW202045537A (zh) * 2019-02-28 2020-12-16 美商健生生物科技公司 化膿性汗腺炎的治療
CA3179228A1 (en) * 2020-04-16 2021-10-21 Janssen Biotech, Inc. Treatment of hidradenitis suppurativa
CN118973579A (zh) * 2022-03-17 2024-11-15 辉瑞公司 用于治疗汗腺炎的方法、剂量方案和组合物

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5407431A (en) 1989-07-11 1995-04-18 Med-Design Inc. Intravenous catheter insertion device with retractable needle
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1994008624A2 (en) 1992-10-14 1994-04-28 Sterling Winthrop Inc. Therapeutic and diagnostic imaging compositions and methods
ATE204299T1 (de) 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper
US5959085A (en) 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9405021D0 (en) 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
DE19943790C2 (de) 1999-09-13 2001-11-15 Ericsson Telefon Ab L M Verfahren und Vorrichtung zur Bestimmung eines Synchronisationsfehlers in einem Netzwerkknoten
US6380129B1 (en) 1999-11-02 2002-04-30 Richard J. Kraemer Enhanced materials for treatment of contamination
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US20020131954A1 (en) 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2007202323C1 (en) 2000-06-29 2012-04-12 Abbvie Inc. Dual specificity antibodies and methods of making and using
US20040086507A1 (en) 2000-10-19 2004-05-06 Kenya Shitara Antibody inhibiting vplf activity
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
AU2002343609B2 (en) 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
EP2295468B1 (en) 2002-02-14 2015-07-08 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
NZ566539A (en) 2002-09-06 2010-01-29 Medarex Inc Therapeutic human anti-IL-1R1 monoclonal antibody
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Amf類を有効成分とする医薬製剤
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
KR100493102B1 (ko) 2003-06-30 2005-06-02 삼성전자주식회사 서브 하우징 스토퍼를 구비하는 휴대용 단말기의 힌지 장치
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
CA2568352C (en) * 2004-06-04 2011-09-13 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat autoinflammatory disease
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
WO2006036936A2 (en) 2004-09-27 2006-04-06 Bridge Pharma, Inc. The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
AU2005314392B2 (en) 2004-12-09 2011-04-14 Centocor, Inc. Anti-integrin immunoconjugates, methods and uses
DE602006014691D1 (de) 2005-08-02 2010-07-15 Xbiotech Inc DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1931383A1 (en) 2005-09-28 2008-06-18 Cytos Biotechnology AG Interleukin-1 conjugates and uses thereof
EP2021026A1 (en) 2006-04-14 2009-02-11 Novartis AG Use of il-i antibodies for treating ophthalmic disorders
ES2384278T3 (es) 2006-05-15 2012-07-03 Xbiotech, Inc IL-1-alfa para su uso en un procedimiento de tratamiento de placas ateroscleróticas
US20110008282A1 (en) 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
DK2109623T3 (da) 2006-05-22 2012-01-30 Xbiotech Inc Cancerbehandling med anti-IL-1-antistoffer
HRP20140172T1 (hr) 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
FR2902659A1 (fr) 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
EP2114443A4 (en) 2006-12-29 2011-08-10 Abbott Lab IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY
CN102056485A (zh) 2008-04-15 2011-05-11 萨可德公司 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂
US8034337B2 (en) 2008-05-30 2011-10-11 Xbiotech, Inc. Interleukin-1α antibodies
AU2009291536B2 (en) 2008-09-12 2012-08-16 Xbiotech Inc. Targeting pathogenic monocytes
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
SG172855A1 (en) 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
AR078650A1 (es) 2009-10-15 2011-11-23 Abbott Lab Anticuerpo de union a il-1 beta
LT2575884T (lt) * 2010-06-03 2018-09-25 Abbvie Biotechnology Ltd Panaudojimai ir kompozicijos, skirti pūlingo hidradenito (hs) gydymui
WO2011159976A2 (en) 2010-06-18 2011-12-22 Xbiotech, Inc. Arthritis treatment
CN103153340A (zh) 2010-08-23 2013-06-12 埃克斯生物科技公司 对肿瘤疾病的治疗
CN103328511B (zh) 2010-09-10 2016-01-20 埃派斯进有限公司 抗-IL-1β抗体及其使用方法
RU2620071C2 (ru) * 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
CN103476933B (zh) * 2011-03-14 2016-04-13 弗洛格有限公司 白介素1受体的拮抗剂
DK2694107T3 (en) 2011-04-01 2018-12-10 Xbiotech Inc TREATMENT OF DERMATOLOGICAL DISORDERS
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
ES2695102T3 (es) 2011-09-23 2019-01-02 Xbiotech Inc Tratamiento para la caquexia
US20130195877A1 (en) 2012-01-31 2013-08-01 Xbiotech, Inc. Treatment of cachexia by targeting interleukin-1 beta
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
KR20150064091A (ko) * 2012-10-04 2015-06-10 엑스바이오테크, 인크. 정신의학적 병태의 치료법
AU2013327501B2 (en) 2012-10-04 2018-08-09 Xbiotech Inc. Treating vascular disease and complications thereof
JP6371758B2 (ja) * 2013-03-12 2018-08-08 全薬工業株式会社 抗ブドウ球菌抗体、その製造方法並びにその使用
US20150024031A1 (en) 2013-07-17 2015-01-22 Baxter International Inc. Methods And Compositions For Reducing Pain, Inflammation, And/Or Immunological Reactions Associated With Parenterally Administering A Primary Therapeutic Agent
KR101753553B1 (ko) 2014-06-03 2017-07-03 엑스바이오테크, 인크. 스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법

Similar Documents

Publication Publication Date Title
JP2020507587A5 (enExample)
François et al. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial
JP2022188083A5 (enExample)
JP2017113019A5 (enExample)
JP2018193377A5 (enExample)
JP2015534578A5 (enExample)
JP2014533279A5 (enExample)
JP2017512193A5 (enExample)
EP4623992A3 (en) Antibodies specifically binding to human il-1r7
JP2017503820A5 (enExample)
JP2011500843A5 (enExample)
JP2015534579A5 (enExample)
JP2016501892A5 (enExample)
RU2018123717A (ru) Комбинированные лечения, их применения и способы
JP2017149726A5 (enExample)
JP2012121878A5 (enExample)
JP2011184466A5 (enExample)
JP2015505564A5 (enExample)
JP2013518912A5 (enExample)
JP2013533858A5 (enExample)
JP2012046518A5 (enExample)
Garrido et al. Medical course and complications after lung transplantation
JP2010500370A5 (enExample)
WO2015191568A3 (en) Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
JP2006514636A5 (enExample)